Stock Analysis
- South Korea
- /
- Commercial Services
- /
- KOSDAQ:A032790
Mgen Solutions Full Year 2023 Earnings: ₩668 loss per share (vs ₩2.68 loss in FY 2022)
Mgen Solutions (KOSDAQ:032790) Full Year 2023 Results
Key Financial Results
- Revenue: ₩90.5b (down 18% from FY 2022).
- Net loss: ₩21.3b (loss widened by ₩21.2b from FY 2022).
- ₩668 loss per share (further deteriorated from ₩2.68 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Mgen Solutions shares are up 23% from a week ago.
Risk Analysis
What about risks? Every company has them, and we've spotted 3 warning signs for Mgen Solutions you should know about.
Valuation is complex, but we're helping make it simple.
Find out whether Mgen Solutions is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About KOSDAQ:A032790
Mgen Solutions
Mgen Solutions Co.,Ltd. manufactures and sells medical equipment.
Flawless balance sheet and overvalued.